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Chemoenzymatic Synthesis of ortho-, meta-, and para-
Substituted Derivatives of l-threo-3-Benzyloxyaspartate,
An Important Glutamate Transporter Blocker
Jandr¦ de Villiers,[a] Marianne de Villiers,[a] Edzard M. Geertsema,[a] Hans Raj,[a, b] and
Gerrit J. Poelarends*[a]
A simple, three-step chemoenzymatic synthesis of l-threo-3-
benzyloxyaspartate (l-TBOA), as well as l-TBOA derivatives
with F, CF3, and CH3 substituents at the aromatic ring, starting
from dimethyl acetylenedicarboxylate was investigated. These
chiral amino acids, which are extremely difficult to prepare by
chemical synthesis, form an important class of inhibitors of ex-
citatory amino acid transporters involved in the regulation of
glutamatergic neurotransmission. In addition, a new chemical
procedure for the synthesis of racemic mixtures of TBOA and
its derivatives was explored. These chemically prepared race-
mates are valuable reference compounds in chiral-phase HPLC
to establish the enantiopurities of the corresponding chemo-
enzymatically prepared amino acids.
l-Glutamate is the major excitatory neurotransmitter in the
mammalian central nervous system and, as such, contributes
to neuronal signaling through its activation of a variety of glu-
tamate-gated ion channels.[1] Excitatory amino acid transport-
ers (EAATs) are responsible for the uptake of glutamate from
the synaptic cleft, which thereby terminates the glutamatergic
neurotransmitter signal.[1, 2] Hence, EAATs present on neurons
and surrounding glia cells play a critical role in regulating syn-
aptic glutamate concentrations. Accumulation of excitotoxic
levels of extracellular glutamate may lead to overactivation of
glutamate-gated ion channels and, consequently, neuronal
injury. Glutamate-mediated neuronal injury has been linked to
several neurological disorders such as amyotrophic lateral scle-
rosis, Alzheimer’s disease, epilepsy, and Huntington’s disease.[3]
Studies on EAATs, of which five subtypes (EAAT1–5) have
been identified, have been largely dependent upon the devel-
opment of selective and potent inhibitors that can be used to
probe the physiological roles of these transporters in the regu-
lation of glutamatergic neurotransmission or in the pathogene-
sis of neurological diseases.[1, 3] Aspartate derivatives with large
aryl or aryloxy substituents at the C3 position form an impor-
tant class of inhibitors of EAATs.[3, 4] This is exemplified by one
of the first EAAT inhibitors to be reported, l-threo-3-benzyloxy-
aspartate (l-TBOA), which is a widely used nontransportable
blocker for all five EAAT subtypes.[4a–c] However, the chemical
synthesis of l-TBOA, the enantiomer of TBOA with the most
potent inhibitory properties, is a highly challenging 11-step
procedure starting from (R)-Garner aldehyde.[4c,d] Therefore,
there is great interest in the development of alternative proce-
dures that provide simple and environmentally friendly access
to l-TBOA and derivatives of l-TBOA with various substituents
on the aromatic ring.
Several research groups have explored ammonia lyases as
biocatalysts in the asymmetric amination of unsaturated acids
to yield chiral a-amino acids.[5] This is a very attractive strategy
for amino acid synthesis, because it makes use of readily avail-
able starting compounds without the requirement for recycling
of cofactors, implementation of dynamic kinetic resolution
strategies, or additional enzymes. The academic and industrial
interest in aspartate derivatives, combined with the potential
advantages of replacing chemical processes with biocatalysis,
has prompted us to focus our attention on methylaspartate
ammonia lyase (MAL).[6] This enzyme catalyzes the reversible
addition of ammonia to mesaconate to give l-threo-3-methyl-
aspartate and l-erythro-3-methylaspartate as products.[7] How-
ever, the wild-type enzyme has a narrow electrophile scope
and only displays amination activity towards fumarate and its
derivatives with a small substituent at the C2 position.[8–10] In-
terestingly, recent protein engineering work on MAL has
shown that a glycine or an alanine mutation at position
Leu384 resulted in mutant enzymes with the ability to aminate
fumarate derivatives with large substituents at the C2 posi-
tion.[10] The synthetic potential of the L384A mutant has been
demonstrated by its use as a biocatalyst in the asymmetric
synthesis of various 3-substituted aspartate derivatives, includ-
ing the important EAAT inhibitor TBOA.[10,11]
In this report, we describe the synthetic potential of the
L384A and L384G mutants of MAL in the selective preparation
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of both enantiomers of TBOA (1a=l-TBOA), as well as a series
of TBOA derivatives (i.e. , 1b–f, 1h, and 1 i) with different sub-
stituents at the ortho, meta, and para positions of the aromatic
ring (Scheme 1). This convenient three-step chemoenzymatic
method for the stereoselective synthesis of TBOA and ring-sub-
stituted derivatives of TBOA (starting from dimethyl acetylene-
dicarboxylate 4) appears to be an elegant alternative for exist-
ing, highly challenging multistep-synthesis procedures.[4c,d]
To investigate the efficiency of the L384G and L384A mu-
tants to aminate 2-benzyloxyfumarate (2a), kinetic parameters
were determined (Table 1). The data indicate that the two MAL
mutants aminate 2a with similar kinetic parameters and cata-
lytic efficiency, having respectable kcat values of 6–7 s
¢1. We
also compared the ability of these mutant enzymes to aminate
2a under optimized reaction conditions (Figure 1). With
0.01 mol% biocatalyst and a 100-fold molar excess of ammonia
(5m) relative to the amount of 2a (50 mm), the reactions were
complete within just a few hours at pH 9.0 and room tempera-
ture, and excellent conversions of >80% were achieved. These
results clearly demonstrate the potential of these mutants for
application in the synthesis of 3-benzyloxyaspartate.
To further demonstrate the synthetic usefulness of the MAL
mutants, a preparative-scale reaction using 0.01 mol% biocata-
lyst (the L384G mutant), ammonia (5m), and 2a (0.75 mmol,
50 mm) was performed at pH 9.0 and room temperature. The
reaction was stopped after 24 h at a final conversion of 90%
(Table 2, entry 1). The amino acid product was purified (78%
yield) and identified as the desired threo isomer of 3-benzyl-
oxyaspartate (de>95%) by comparison of its 1H NMR signals
to those of chemically synthesized authentic standards with
known threo or erythro configuration (see the Supporting Infor-
mation). No other regio- or diastereoisomer was observed. The
absolute configuration of the product was determined by
high-performance liquid chromatography (HPLC) on a chiral
stationary phase by using chemically prepared authentic stand-
ards with known dl-threo or l-threo configuration (Figure S3,
Supporting Information). This analysis revealed that the prod-
uct had the l-threo configuration and was present as a single
enantiomer (1a, l-TBOA; ee>99%).
The preparative-scale experiment was repeated under identi-
cal conditions but by using the L384A mutant as a biocatalyst
instead of the L384G mutant. Analysis of the isolated amino
acid product revealed that the L384A-catalyzed amination of
2a was also highly regio- and stereoselective and that l-TBOA
was exclusively produced (de>95%, ee>99%). We also ex-
plored the L384A mutant for the kinetic resolution of a racemic
mixture of dl-TBOA (5 mg, 0.021 mmol) in an analytical-scale
experiment. The reaction was followed by monitoring sub-
strate depletion and product formation by HPLC on a chiral
stationary phase. With 0.1 mol% biocatalyst, the reaction was
complete within 24 h at pH 8.0 and room temperature, and
Scheme 1. Chemoenzymatic synthesis of TBOA and its derivatives by using either the L384G or L384A mutant of MAL as biocatalyst. DABCO=1,4-diazabicy-
clo[2.2.2]octane.
Table 1. Apparent kinetic parameters for the MAL(L384A)- and










L384A 6.80.3 181.9 43866 378
L384G 6.50.2 121 41056 542
[a] Each experiment was done in triplicate. Errors are standard deviations
from each fit. kcat= turnover number, Km=Michaelis constant.
Figure 1. Enzyme-catalyzed transformations under optimized reaction condi-
tions. Progress curves for the L384A- and L384G-catalyzed (0.01 mol%) addi-
tion of ammonia (5m) to 2-benzyloxyfumarate (2a, 50 mm), as monitored by
1H NMR spectroscopy.
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near 50% conversion of the starting material was achieved
(Figure S9). The remaining amino acid product, d-TBOA, had
an ee value of >95%. Taken together, the results clearly dem-
onstrate the potential of the L384A and L384G mutants for the
selective preparation of both enantiomers of TBOA.
Next, a series of 2-benzyloxyfumarate derivatives 2b–j
(Scheme 1) was prepared from dimethyl acetylenedicarboxy-
late (4) and evaluated as substrates for the L384G and L384A
mutants. The ability of these MAL mutants to catalyze the ami-
nation of substrates with a small (e.g. , F) or more bulky (e.g. ,
CF3 and CH3) substituent at the ortho, meta, or para position of
the aromatic ring (i.e. , 2b–j) was tested by using 1H NMR spec-
troscopy (Table 2). The L384A mutant displayed activity for 2-
benzyloxyfumarate derivatives 2b–e, 2h, and 2 i. Reaction mix-
tures were incubated at pH 9.0 and room temperature, and
conversions of >50% after 3 h and >90% after 24 h were
achieved. Strikingly, mutant L384G not only showed activity for
compounds 2b–e, 2h, and 2 i, but it also processed 2-benzyl-
oxyfumarate derivative 2 f, which was not converted at all by
the L384A mutant. Again, excellent conversions were achieved
after incubation for 24 h at pH 9.0 and room temperature. The
aryl binding pocket of the L384G mutant is most likely slightly
larger than that of the L384A mutant,[10] and this rationalizes
its ability to convert compound 2 f, which carries a large tri-
fluoromethyl group at the meta position. Compounds with
a trifluoromethyl (2g) or methyl (2 j) substituent at the para
position were not accepted as substrates by the L384A mutant
nor the L384G mutant. Because the L384G mutant showed
a larger substrate scope, it was selected as the biocatalyst for
application in preparative-scale reactions.
Preparative-scale experiments were performed to allow un-
ambiguous product identification by HRMS and 1H NMR,
13C NMR, and/or 19F NMR spectroscopy and thus to ascertain
that the L384G-catalyzed amination of 2b–f, 2h, and 2 i yields
the corresponding amino acid products 1b–f, 1h, and 1 i
(Scheme 1). Ammonia (5m), 2-benzyloxyfumarate derivative
(0.75 mmol, 50 mm), and biocatalyst (either 0.01 or 0.05 mol%)
were incubated at pH 9.0 and room temperature, and reactions
were stopped after 24 h, which resulted in excellent conver-
sions of >89% (Table 2). The products were purified (57–77%
yield) and identified as the corresponding 3-benzyloxyaspar-
tate derivatives 1b–f, 1h, and 1 i. Amino acid product 1 i was
further identified as the desired threo isomer of 3-(3-methyl)-
benzyloxyaspartate (de>95%) by comparison of its 1H NMR
signals to those of chemically synthesized authentic standards
with known threo or erythro configuration. Although the rela-
tive configuration of products 1b–f and 1h was not deter-
mined by comparison to authentic standards, we assume the
relative configuration to be threo for all products on the basis
of analogy (see the Supporting Information).[10] Analysis of
products 1c, 1 f, and 1 i by HPLC on a chiral stationary phase
by using chemically prepared authentic standards with known
dl-threo configuration revealed that the L384G-catalyzed ami-
nation reactions were highly enantioselective and that these
amino acids were produced with >99%ee (Table 2; Fig-
ures S5–S7). Control experiments showed that the 2-benzyloxy-
fumarate derivatives did not undergo amination in the ab-
sence of the enzyme. These results show that the L384G
mutant has striking potential for application in the regio- and
stereoselective synthesis of derivatives of TBOA.
In conclusion, we demonstrated the chemoenzymatic syn-
thesis of l-threo-3-benzyloxyaspartate (l-TBOA) and various de-
rivatives of TBOA with substituents on the aromatic ring by
asymmetric amination of 2-benzyloxyfumarate derivatives by
using engineered methylaspartate ammonia lyase variants.
This chemoenzymatic approach appears to be an elegant alter-
native for existing chemical methods.[4a–d] This was convincing-
ly demonstrated by the 3-step chemoenzymatic synthesis of
l-TBOA, the selective chemical preparation of which is a highly
challenging 11-step procedure starting from (R)-Garner aldehy-
de.[4c] Appropriate experiments to investigate the inhibitory
properties of the newly synthesized TBOA derivatives against
aspartate/glutamate transporters are underway.
Table 2. MAL(L384A)- and MAL(L384G)-catalyzed addition of ammonia to fumarate derivatives 2a–j.
Entry Fumarate derivative Product Catalyst [mol%] L384A conversion [%] L384G conversion [%] Yield [%][a] de [%][b] ee [%]
3 h 24 h 3 h 24 h
1 2a 1a 0.01 88 95 83 90 78 >95[c] >99[e]
2 2b 1b 0.01 54 91 45 89 60 >95[d] ND[f]
3 2c 1c 0.01 95 95 93 94 61 >95[d] >99[e]
4 2d 1d 0.01 62 94 88 92 57 >95[d] ND[f]
5 2e 1e 0.05 61 95 50 92 58 >95[d] ND[f]
6 2 f 1 f 0.05 0 0 92 94 77 >95[d] >99[e]
7 2g – 0.05 0 0 0 0 – – –
8 2h 1h 0.05 91 92 86 90 71 >95[d] ND[f]
9 2 i 1 i 0.05 91 93 92 95 73 >95[c] >99[e]
10 2 j – 0.05 0 0 0 0 – – –
[a] Yield of isolated product after ion-exchange chromatography. [b] The diastereomeric excess (de) is defined as the excess of threo isomer over the erythro
isomer. [c] The purified amino acid product had the threo configuration, as determined by comparison of its 1H NMR signals to those of chemically synthe-
sized authentic standards with known threo or erythro configuration. [d] The purified amino acid product was tentatively assigned the threo configuration
on the basis of analogy (see the Supporting Information). [e] The enantiomeric excess of the isolated product was determined by HPLC on a chiral station-
ary phase by using a chemically synthesized authentic standard with known dl-threo configuration. [f] ND=not determined; however, the optical rotations
of products 1b, 1d, 1e, and 1h (in terms of both signs and values) are identical to those of enantiopure products 1a, 1c, 1 f, and 1 i (Table S1), which
may suggest high optical purity for products 1b, 1d, 1e, and 1h.
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